# PureTech Health to Present LYT-200 Phase 1b Data and Advance to Phase 2

- URL: https://stocks.freetheai.org/news/puretech-health-to-present-lyt-200-phase-1b-data-and-advance-to-phase-2-80dad5
- Published: 2026-10-19T06:00:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [LSE:PRTC](https://stocks.freetheai.org/symbols/LSE-PRTC)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

PureTech Health PLC (LSE:PRTC) announced it will present completed Phase 1b clinical trial data for its investigational candidate, LYT-200, at the ESMO 2026 conference on October 24 in Madrid. The upcoming oral presentation will detail results in patients with relapsed or refractory high-risk myelodysplastic syndromes and acute myeloid leukemia.

The completed trial findings support advancing LYT-200 into Phase 2 development. LYT-200 is a galectin-9 antibody designed to target rare and difficult-to-treat blood cancers. The drug candidate has previously received FDA Fast Track designation for both indications, which can help accelerate clinical development and regulatory evaluation.

Following the announcement, shares of PureTech Health were trading at 114.6 GBX, up 0.53% for the day. Investors will be tracking the full oral presentation at ESMO for details on efficacy and safety, as well as timeline updates regarding the start of Phase 2 studies.

## Key points

- PureTech Health will present completed Phase 1b data for LYT-200 at ESMO 2026 on October 24 in Madrid.
- The trial evaluated LYT-200 in patients with relapsed or refractory high-risk MDS and AML.
- The completed Phase 1b results support plans to advance LYT-200 into Phase 2 clinical development.
- LYT-200 is a galectin-9 antibody with FDA Fast Track designation for both indications.

## Questions and answers

### When will PureTech Health present the LYT-200 Phase 1b data?

PureTech Health will present completed Phase 1b results for LYT-200 during an oral presentation at ESMO 2026 on October 24 in Madrid.

### What conditions does LYT-200 target?

LYT-200 is a galectin-9 antibody targeting relapsed or refractory high-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukemia (AML).

### What are the next development steps for LYT-200?

The Phase 1b trial data support moving LYT-200 into Phase 2 clinical trials. The candidate also holds FDA Fast Track designation for both HR-MDS and AML.